Literature DB >> 26399644

Immune-Inflammatory and Oxidative and Nitrosative Stress Biomarkers of Depression Symptoms in Subjects with Multiple Sclerosis: Increased Peripheral Inflammation but Less Acute Neuroinflammation.

Ana Paula Kallaur1, Josiane Lopes1, Sayonara Rangel Oliveira2, Andrea Name Colado Simão2, Edna Maria Vissoci Reiche2, Elaine Regina Delicato de Almeida2, Helena Kaminami Morimoto2, Wildea Lice Carvalho Jennings de Pereira2, Daniele Frizon Alfieri2, Sueli Donizete Borelli3, Domacio Ramon Kaimen-Maciel4,5, Michael Maes6,7,8.   

Abstract

There is evidence that activated immune-inflammatory and oxidative and nitrosative stress (IO&NS) pathways play a role in the pathophysiology of multiple sclerosis (MS) and depression. This study examines serum levels of interleukin (IL)-1β, IL-4, IL-6, and IL-10; peroxides (LOOH); nitric oxide metabolites (NOx); albumin; ferritin; C-reactive protein (CRP); and tumor necrosis factor (TNF)-β NcoI polymorphism (rs909253) and gadolinium-enhanced magnetic resonance imaging (MRI) scan in MS patients with (n = 42) and without (n = 108) depression and normal controls (n = 249). Depression is scored using the depressive subscale of the Hospital Anxiety and Depression Scale (HADS). The extent of neurological disability is measured using the Expanded Disability Status Scale (EDSS) at the same time of the abovementioned measurements and 5 years earlier. Disease progression is assessed as actual EDSS-EDSS 5 years earlier. Three variables discriminate MS patients with depression from those without depression, i.e., increased IL-6 and lower IL-4 and albumin. Binary logistic regression showed that MS with depression (versus no depression) was characterized by more gastrointestinal symptoms and disease progression, higher serum IL-6, and lower albumin levels. In subjects with MS, the HADS score was significantly predicted by three EDSS symptoms, i.e., pyramidal, gastrointestinal, and visual symptoms. Fifty-eight percent of the variance in the HADS score was predicted by gastrointestinal symptoms, visual symptoms, the TNFB1/B2 genotype, and contrast enhancement (both inversely associated). There were no significant associations between depression in MS and type of MS, duration of illness, age, sex, nicotine dependence, and body mass index. MS with depression is associated with signs of peripheral inflammation, more disability, disease progression, gastrointestinal and visual symptoms, but less contrast enhancement as compared to MS without depression. It is concluded that depression is part of the neurological symptoms of MS and that its expression is primed by peripheral inflammation while acute neuroinflammation and the TNFB1/B2 genotype may be protective.

Entities:  

Keywords:  Autoimmune; Cytokines; Depression; Immune; Inflammation; Multiple sclerosis; Oxidative and nitrosative stress

Mesh:

Substances:

Year:  2015        PMID: 26399644     DOI: 10.1007/s12035-015-9443-4

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  74 in total

1.  Cytokine accumulations in CSF of multiple sclerosis patients: frequent detection of interleukin-1 and tumor necrosis factor but not interleukin-6.

Authors:  S L Hauser; T H Doolittle; R Lincoln; R H Brown; C A Dinarello
Journal:  Neurology       Date:  1990-11       Impact factor: 9.910

Review 2.  Nitric oxide and multiple sclerosis.

Authors:  Juan Manuel Encinas; Louis Manganas; Grigori Enikolopov
Journal:  Curr Neurol Neurosci Rep       Date:  2005-05       Impact factor: 5.081

Review 3.  A review on the oxidative and nitrosative stress (O&NS) pathways in major depression and their possible contribution to the (neuro)degenerative processes in that illness.

Authors:  Michael Maes; Piotr Galecki; Yong Seun Chang; Michael Berk
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2010-05-12       Impact factor: 5.067

4.  MRI contrast uptake in new lesions in relapsing-remitting MS followed at weekly intervals.

Authors:  Francois Cotton; Howard L Weiner; Ferenc A Jolesz; Charles R G Guttmann
Journal:  Neurology       Date:  2003-02-25       Impact factor: 9.910

5.  Hydroperoxide-initiated chemiluminescence: an assay for oxidative stress in biopsies of heart, liver, and muscle.

Authors:  B Gonzalez Flecha; S Llesuy; A Boveris
Journal:  Free Radic Biol Med       Date:  1991       Impact factor: 7.376

6.  Validation of the Hospital Anxiety and Depression Scale for use with multiple sclerosis patients.

Authors:  Kimia Honarmand; Anthony Feinstein
Journal:  Mult Scler       Date:  2009-11-13       Impact factor: 6.312

7.  Interleukin-6 is elevated in plasma in multiple sclerosis.

Authors:  K Frei; S Fredrikson; A Fontana; H Link
Journal:  J Neuroimmunol       Date:  1991-02       Impact factor: 3.478

8.  Dysregulated T cell expression of TIM3 in multiple sclerosis.

Authors:  Ken Koguchi; David E Anderson; Li Yang; Kevin C O'Connor; Vijay K Kuchroo; David A Hafler
Journal:  J Exp Med       Date:  2006-06-05       Impact factor: 14.307

Review 9.  Myalgic encephalomyelitis/chronic fatigue syndrome and encephalomyelitis disseminata/multiple sclerosis show remarkable levels of similarity in phenomenology and neuroimmune characteristics.

Authors:  Gerwyn Morris; Michael Maes
Journal:  BMC Med       Date:  2013-09-17       Impact factor: 8.775

10.  Depressive symptoms in multiple sclerosis from an in vivo study with TBSS.

Authors:  Yujuan Shen; Lijun Bai; Ying Gao; Fangyuan Cui; Zhongjian Tan; Yin Tao; Chuanzhu Sun; Li Zhou
Journal:  Biomed Res Int       Date:  2014-05-04       Impact factor: 3.411

View more
  19 in total

Review 1.  Imaging and depression in multiple sclerosis: a historical perspective.

Authors:  Fabio Giuseppe Masuccio; Giulia Gamberini; Massimiliano Calabrese; Claudio Solaro
Journal:  Neurol Sci       Date:  2021-01-07       Impact factor: 3.307

2.  Disability in multiple sclerosis is associated with age and inflammatory, metabolic and oxidative/nitrosative stress biomarkers: results of multivariate and machine learning procedures.

Authors:  Tamires Flauzino; Andrea Name Colado Simão; Wildea Lice de Carvalho Jennings Pereira; Daniela Frizon Alfieri; Sayonara Rangel Oliveira; Ana Paula Kallaur; Marcell Alysson Batisti Lozovoy; Damacio Ramón Kaimen-Maciel; Michael Maes; Edna Maria Vissoci Reiche
Journal:  Metab Brain Dis       Date:  2019-07-13       Impact factor: 3.584

Review 3.  False dogmas in mood disorders research: Towards a nomothetic network approach.

Authors:  Michael Hj Maes; Drozdstoy Stoyanov
Journal:  World J Psychiatry       Date:  2022-05-19

Review 4.  Depression in Multiple Sclerosis: Epidemiology, Aetiology, Diagnosis and Treatment.

Authors:  Claudio Solaro; Giulia Gamberini; Fabio Giuseppe Masuccio
Journal:  CNS Drugs       Date:  2018-02       Impact factor: 5.749

5.  Residual Effects of Restless Sleep over Depressive Symptoms on Chronic Medical Conditions: Race by Gender Differences.

Authors:  Shervin Assari; Amanda Sonnega; Renee Pepin; Amanda Leggett
Journal:  J Racial Ethn Health Disparities       Date:  2016-01-28

6.  Qualitative study identifies life shifts and stress coping strategies in people with multiple sclerosis.

Authors:  Heidemarie Lex; Pollie Price; Lauren Clark
Journal:  Sci Rep       Date:  2022-04-20       Impact factor: 4.996

Review 7.  Integrating Interleukin-6 into depression diagnosis and treatment.

Authors:  Georgia E Hodes; Caroline Ménard; Scott J Russo
Journal:  Neurobiol Stress       Date:  2016-03-29

Review 8.  Peripheral Inflammatory Parameters in Late-Life Depression: A Systematic Review.

Authors:  Mónica Martínez-Cengotitabengoa; Lucía Carrascón; John T O'Brien; María-José Díaz-Gutiérrez; Cristina Bermúdez-Ampudia; Kenji Sanada; Marta Arrasate; Ana González-Pinto
Journal:  Int J Mol Sci       Date:  2016-12-02       Impact factor: 5.923

Review 9.  Multiple Sclerosis: Immunopathology and Treatment Update.

Authors:  Narges Dargahi; Maria Katsara; Theodore Tselios; Maria-Eleni Androutsou; Maximilian de Courten; John Matsoukas; Vasso Apostolopoulos
Journal:  Brain Sci       Date:  2017-07-07

10.  Increased Oxidative Stress Toxicity and Lowered Antioxidant Defenses in Temporal Lobe Epilepsy and Mesial Temporal Sclerosis: Associations with Psychiatric Comorbidities.

Authors:  Michael Maes; Thitiporn Supasitthumrong; Chusak Limotai; Ana Paula Michelin; Andressa Keiko Matsumoto; Laura de Oliveira Semão; João Victor de Lima Pedrão; Estefânia Gastaldello Moreira; Andre F Carvalho; Sunee Sirivichayakul; Décio Sabbatini Barbosa; Buranee Kanchanatawan
Journal:  Mol Neurobiol       Date:  2020-06-09       Impact factor: 5.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.